raloxifene ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives 2351 84449-90-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • raloxifene
  • keoxifene
  • raloxifene hydrochloride
  • evista
  • raloxifene HCl
A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
  • Molecular weight: 473.59
  • Formula: C28H27NO4S
  • CLOGP: 6.86
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 2
  • TPSA: 70
  • ALOGS: -5.97
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.12 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 2 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 7.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 10.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 9, 1997 FDA LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Endometrial cancer 249.05 12.10 77 19832 2806 50582409
Breast cancer 221.82 12.10 162 19747 42728 50542487
Deep vein thrombosis 157.38 12.10 168 19741 73136 50512079
Retinal vein thrombosis 143.84 12.10 33 19876 364 50584851
Bone density decreased 142.91 12.10 75 19834 11000 50574215
Pulmonary embolism 122.22 12.10 174 19735 101530 50483685
Fracture 104.15 12.10 71 19838 16762 50568453
Spinal compression fracture 99.42 12.10 62 19847 12594 50572621
Femur fracture 98.80 12.10 96 19813 37368 50547847
Retinal vein occlusion 81.83 12.10 30 19879 1851 50583364
Breast cancer female 81.55 12.10 44 19865 6818 50578397
Hip fracture 77.04 12.10 71 19838 25860 50559355
Transient ischaemic attack 69.35 12.10 74 19835 32136 50553079
Body height decreased 65.85 12.10 42 19867 8866 50576349
Thoracic vertebral fracture 65.44 12.10 32 19877 4041 50581174
Cerebral infarction 63.88 12.10 59 19850 21545 50563670
Compression fracture 62.66 12.10 35 19874 5802 50579413
Breast cancer in situ 59.22 12.10 22 19887 1409 50583806
Lumbar vertebral fracture 58.92 12.10 31 19878 4566 50580649
Fall 58.87 12.10 274 19635 334658 50250557
Pelvic fracture 58.32 12.10 43 19866 11477 50573738
Drug ineffective 57.58 12.10 151 19758 819182 49766033
Oestrogen receptor assay positive 56.50 12.10 16 19893 427 50584788
Spinal fracture 54.93 12.10 47 19862 15526 50569689
Toxicity to various agents 52.50 12.10 10 19899 212489 50372726
Cerebrovascular accident 52.04 12.10 115 19794 94565 50490650
Visual acuity reduced 48.25 12.10 49 19860 20090 50565125
Osteonecrosis of jaw 45.56 12.10 60 19849 32466 50552749
Low turnover osteopathy 43.01 12.10 24 19885 3970 50581245
Ovarian cancer 42.40 12.10 26 19883 5123 50580092
Endometrial cancer stage I 42.04 12.10 11 19898 216 50584999
Product use issue 41.56 12.10 5 19904 149470 50435745
Muscle spasms 41.53 12.10 126 19783 125427 50459788
Wrist fracture 41.19 12.10 35 19874 11452 50573763
Off label use 40.02 12.10 79 19830 474347 50110868
Infusion related reaction 39.76 12.10 9 19900 169548 50415667
Postmenopausal haemorrhage 39.31 12.10 18 19891 1962 50583253
Osteonecrosis 38.67 12.10 46 19863 22471 50562744
Hot flush 38.19 12.10 65 19844 44104 50541111
Retinal vascular thrombosis 35.40 12.10 9 19900 157 50585058
Product complaint 35.23 12.10 32 19877 11434 50573781
Blindness unilateral 34.57 12.10 23 19886 5212 50580003
Systemic lupus erythematosus 33.91 12.10 7 19902 140615 50444600
Uterine cancer 33.28 12.10 20 19889 3800 50581415
Synovitis 32.40 12.10 5 19904 123860 50461355
Rheumatoid arthritis 32.13 12.10 20 19889 202530 50382685
Myocardial infarction 31.95 12.10 92 19817 88935 50496280
Uterine polyp 31.77 12.10 15 19894 1753 50583462
Treatment failure 30.90 12.10 8 19901 137629 50447586
Drug intolerance 30.35 12.10 25 19884 219079 50366136
Glossodynia 29.47 12.10 5 19904 115564 50469651
Cataract 28.90 12.10 60 19849 47240 50537975
Endometrial cancer stage II 28.72 12.10 5 19904 10 50585205
Multiple fractures 27.58 12.10 22 19887 6589 50578626
Stress fracture 26.83 12.10 22 19887 6853 50578362
Hyperlipidaemia 25.63 12.10 33 19876 17457 50567758
Intestinal pseudo-obstruction 25.48 12.10 10 19899 744 50584471
Oedema peripheral 25.31 12.10 126 19783 157835 50427380
Retinal haemorrhage 25.23 12.10 18 19891 4563 50580652
Rib fracture 24.69 12.10 34 19875 19187 50566028
Therapeutic product effect decreased 23.63 12.10 12 19897 136038 50449177
Therapeutic product effect incomplete 23.24 12.10 4 19905 91511 50493704
Alopecia 23.12 12.10 38 19871 245009 50340206
Embolism 22.50 12.10 20 19889 6948 50578267
Lower respiratory tract infection 22.41 12.10 5 19904 95196 50490019
Lumbar spinal stenosis 22.14 12.10 16 19893 4138 50581077
Injection site haemorrhage 21.96 12.10 34 19875 21312 50563903
Embolism venous 21.43 12.10 13 19896 2512 50582703
Femoral neck fracture 21.26 12.10 20 19889 7470 50577745
Breast cancer recurrent 21.06 12.10 15 19894 3793 50581422
Oestrogen receptor assay negative 20.52 12.10 3 19906 0 50585215
Peripheral swelling 20.30 12.10 31 19878 205905 50379310
Ischaemic stroke 20.17 12.10 28 19881 15920 50569295
Joint swelling 19.64 12.10 42 19867 245244 50339971
Dementia Alzheimer's type 19.28 12.10 9 19900 1025 50584190
Fibrocystic breast disease 18.87 12.10 9 19900 1075 50584140
Intramedullary rod insertion 18.80 12.10 11 19898 1989 50583226
Pericarditis 18.79 12.10 4 19905 78685 50506530
Endometrial hyperplasia 18.78 12.10 8 19901 734 50584481
Osteopenia 18.77 12.10 28 19881 16990 50568225
Diverticulum 18.74 12.10 22 19887 10592 50574623
Back pain 18.58 12.10 149 19760 219881 50365334
Uterine leiomyoma 18.53 12.10 19 19890 7872 50577343
Thrombosis 18.40 12.10 56 19853 55777 50529438
Spinal osteoarthritis 18.21 12.10 25 19884 14067 50571148
Intentional product use issue 18.18 12.10 4 19905 76914 50508301
Swelling 18.15 12.10 32 19877 200840 50384375
Bone pain 18.10 12.10 50 19859 47179 50538036
Pain 17.46 12.10 145 19764 578758 50006457
Humerus fracture 17.27 12.10 18 19891 7600 50577615
General physical health deterioration 16.52 12.10 19 19890 142415 50442800
Infection 16.13 12.10 27 19882 172927 50412288
Breast swelling 15.86 12.10 8 19901 1079 50584136
Colitis ischaemic 15.67 12.10 19 19890 9464 50575751
Insulinoma 15.46 12.10 4 19905 75 50585140
Foot fracture 15.33 12.10 28 19881 20063 50565152
Blood calcium increased 15.32 12.10 17 19892 7702 50577513
Colon cancer 15.32 12.10 18 19891 8673 50576542
Feeling abnormal 15.31 12.10 93 19816 125399 50459816
Hepatic enzyme increased 15.22 12.10 19 19890 137361 50447854
Gastrooesophageal reflux disease 15.21 12.10 65 19844 76363 50508852
Lung neoplasm malignant 15.01 12.10 24 19885 15460 50569755
Kyphosis 14.95 12.10 10 19899 2285 50582930
Thrombotic stroke 14.80 12.10 6 19903 486 50584729
Wound 14.72 12.10 12 19897 105782 50479433
Fractured sacrum 14.60 12.10 9 19900 1789 50583426
Drug abuse 14.37 12.10 3 19906 59843 50525372
Pleurisy 14.30 12.10 16 19893 7315 50577900
Endometrial hypertrophy 14.22 12.10 5 19904 273 50584942
Coronary artery disease 13.99 12.10 34 19875 29692 50555523
Breast cancer stage III 13.94 12.10 11 19898 3245 50581970
Product use in unapproved indication 13.92 12.10 15 19894 115804 50469411
Intervertebral disc protrusion 13.80 12.10 27 19882 20366 50564849
Jaw disorder 13.65 12.10 13 19896 4930 50580285
Subacute hepatic failure 13.61 12.10 4 19905 122 50585093
Haemorrhage subcutaneous 13.48 12.10 10 19899 2691 50582524
Gastrointestinal tract adenoma 13.45 12.10 5 19904 321 50584894
Intentional overdose 13.34 12.10 4 19905 62500 50522715
Osteomyelitis 13.23 12.10 28 19881 22325 50562890
Sarcoma uterus 13.17 12.10 3 19906 32 50585183
Erythema multiforme 13.14 12.10 17 19892 9033 50576182
Atrophic vulvovaginitis 12.99 12.10 8 19901 1588 50583627
Fracture nonunion 12.93 12.10 9 19900 2195 50583020
Bone disorder 12.90 12.10 25 19884 18727 50566488
Tibia fracture 12.80 12.10 12 19897 4463 50580752
Vision blurred 12.76 12.10 63 19846 78584 50506631
Road traffic accident 12.71 12.10 29 19880 24323 50560892
Breast calcifications 12.60 12.10 7 19902 1148 50584067
Ligament sprain 12.60 12.10 18 19891 10507 50574708
Fatigue 12.40 12.10 200 19709 707401 49877814
Glaucoma 12.14 12.10 22 19887 15664 50569551
Osteoporotic fracture 12.14 12.10 10 19899 3135 50582080

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Endometrial cancer 156.48 12.66 43 14153 1867 64482669
Bone density decreased 131.06 12.66 57 14139 9895 64474641
Breast cancer 108.66 12.66 72 14124 29076 64455460
Retinal vein thrombosis 104.91 12.66 25 14171 608 64483928
Deep vein thrombosis 97.65 12.66 118 14078 105064 64379472
Spinal compression fracture 95.48 12.66 52 14144 14723 64469813
Breast cancer female 83.11 12.66 34 14162 5069 64479467
Thoracic vertebral fracture 79.87 12.66 32 14164 4521 64480015
Femur fracture 76.47 12.66 62 14134 34073 64450463
Oestrogen receptor assay positive 72.68 12.66 16 14180 270 64484266
Pulmonary embolism 71.63 12.66 121 14075 146235 64338301
Body height decreased 67.31 12.66 33 14163 7521 64477015
Fracture 64.31 12.66 44 14152 18711 64465825
Hip fracture 58.13 12.66 48 14148 27051 64457485
Lumbar vertebral fracture 58.05 12.66 27 14169 5475 64479061
Transient ischaemic attack 53.60 12.66 57 14139 44125 64440411
Retinal vein occlusion 52.41 12.66 21 14175 2967 64481569
Endometrial cancer stage I 52.23 12.66 11 14185 149 64484387
Toxicity to various agents 51.52 12.66 9 14187 363504 64121032
Spinal fracture 50.61 12.66 35 14161 15139 64469397
Wrist fracture 48.00 12.66 29 14167 9972 64474564
Compression fracture 47.90 12.66 24 14172 5728 64478808
Pelvic fracture 46.54 12.66 29 14167 10534 64474002
Fall 42.64 12.66 193 14003 416633 64067903
Breast cancer in situ 42.00 12.66 13 14183 859 64483677
Product complaint 40.87 12.66 28 14168 11926 64472610
Postmenopausal haemorrhage 39.41 12.66 14 14182 1421 64483115
Visual acuity reduced 38.32 12.66 38 14158 27103 64457433
Cerebrovascular accident 37.35 12.66 89 14107 137494 64347042
Muscle spasms 36.97 12.66 90 14106 140933 64343603
Hot flush 36.68 12.66 48 14148 46187 64438349
Multiple fractures 35.56 12.66 20 14176 6020 64478516
Endometrial cancer stage II 34.17 12.66 5 14191 4 64484532
Ovarian cancer 34.12 12.66 16 14180 3303 64481233
Off label use 33.43 12.66 55 14141 632751 63851785
Uterine polyp 32.93 12.66 12 14184 1310 64483226
Osteonecrosis of jaw 31.06 12.66 41 14155 39784 64444752
Injection site haemorrhage 30.64 12.66 32 14164 24246 64460290
Uterine cancer 29.89 12.66 14 14182 2884 64481652
Completed suicide 26.89 12.66 8 14188 224406 64260130
Osteonecrosis 26.69 12.66 32 14164 28197 64456339
Bone pain 25.47 12.66 41 14155 47531 64437005
Death 24.49 12.66 43 14153 482662 64001874
Drug ineffective 23.09 12.66 101 14095 840146 63644390
Oedema peripheral 22.65 12.66 99 14097 210218 64274318
Cerebral infarction 21.46 12.66 35 14161 41009 64443527
Blindness unilateral 21.15 12.66 15 14181 6746 64477790
Feeling abnormal 21.05 12.66 71 14125 133531 64351005
Cataract 20.68 12.66 39 14157 51223 64433313
Hyperlipidaemia 20.02 12.66 25 14171 22951 64461585
Low turnover osteopathy 19.17 12.66 9 14187 1864 64482672
Product use issue 18.93 12.66 5 14191 151710 64332826
Intestinal pseudo-obstruction 18.60 12.66 9 14187 1991 64482545
Ischaemic stroke 18.31 12.66 27 14169 29008 64455528
Endometrial hyperplasia 18.06 12.66 6 14190 498 64484038
Blood calcium increased 18.04 12.66 15 14181 8527 64476009
Intervertebral disc degeneration 17.83 12.66 18 14178 13102 64471434
Acute kidney injury 17.78 12.66 46 14150 449194 64035342
Diverticulum 17.75 12.66 18 14178 13180 64471356
Infusion related reaction 17.73 12.66 7 14189 164460 64320076
Myocardial infarction 17.04 12.66 77 14119 165744 64318792
Uterine leiomyoma 17.00 12.66 12 14184 5357 64479179
Insulinoma 16.87 12.66 4 14192 95 64484441
Back pain 16.65 12.66 103 14093 250068 64234468
Stress fracture 16.50 12.66 12 14184 5612 64478924
Foot fracture 16.21 12.66 20 14176 18137 64466399
Atrophic vulvovaginitis 16.20 12.66 7 14189 1194 64483342
Femoral neck fracture 15.74 12.66 14 14182 8710 64475826
Retinal haemorrhage 15.64 12.66 13 14183 7385 64477151
Injection site erythema 15.25 12.66 42 14154 70758 64413778
Osteomyelitis 15.07 12.66 24 14172 27563 64456973
Fractured sacrum 14.82 12.66 7 14189 1468 64483068
Endometrial hypertrophy 14.75 12.66 4 14192 165 64484371
Neutropenia 14.38 12.66 19 14177 239605 64244931
Dementia Alzheimer's type 14.10 12.66 6 14190 986 64483550
Osteoarthritis 14.07 12.66 38 14158 63298 64421238
Vascular headache 13.96 12.66 3 14193 45 64484491
Jaw disorder 13.88 12.66 10 14186 4607 64479929
Gastrooesophageal reflux disease 13.82 12.66 45 14151 83098 64401438
Breast swelling 13.78 12.66 6 14190 1042 64483494
Breast cancer recurrent 13.72 12.66 8 14188 2575 64481961
Osteoporotic fracture 13.67 12.66 9 14187 3589 64480947
Tibia fracture 13.64 12.66 10 14186 4735 64479801
Benign vulval neoplasm 13.55 12.66 3 14193 52 64484484
General physical health deterioration 13.55 12.66 15 14181 204410 64280126
Erythema multiforme 13.55 12.66 17 14179 15684 64468852
Multiple organ dysfunction syndrome 13.31 12.66 3 14193 101410 64383126
Fibrocystic breast disease 13.29 12.66 5 14191 597 64483939
Rib fracture 13.25 12.66 21 14175 24017 64460519
Bone disorder 12.67 12.66 17 14179 16742 64467794

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03XC01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Selective estrogen receptor modulators
FDA MoA N0000000168 Selective Estrogen Receptor Modulators
CHEBI has role CHEBI:50646 antiosteoporotic
CHEBI has role CHEBI:50837 oestrogen antagonist
FDA EPC N0000175826 Estrogen Agonist/Antagonist
MeSH PA D050071 Bone Density Conservation Agents
MeSH PA D004965 Estrogen Antagonists
MeSH PA D020847 Estrogen Receptor Modulators
MeSH PA D006727 Hormone Antagonists
MeSH PA D020845 Selective Estrogen Receptor Modulators

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Postmenopausal osteoporosis indication 102447009
Prevention of Breast Carcinoma indication
Prevention of Glucocorticoid-Induced Osteoporosis off-label use
Lupus anticoagulant disorder contraindication 19267009
Hypertensive disorder contraindication 38341003 DOID:10763
Thrombosis of retinal vein contraindication 46085004
Chronic heart failure contraindication 48447003
Atrial fibrillation contraindication 49436004 DOID:0060224
Thrombophlebitis contraindication 64156001 DOID:3875
Deep venous thrombosis contraindication 128053003
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Transient ischemic attack contraindication 266257000 DOID:224
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.13 acidic
pKa2 8.6 acidic
pKa3 9.15 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor ANTAGONIST IC50 9.40 WOMBAT-PK IUPHAR
Estrogen receptor beta Nuclear hormone receptor MODULATOR EC50 8 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR Ki 6.41 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 5.93 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 6.21 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.42 CHEMBL
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme Ki 9 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 5.72 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.55 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.38 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.16 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 6.21 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.30 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 5.77 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.28 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 8.54 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 6.52 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 6.97 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.83 DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor EC50 4.93 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 6.32 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 6.19 DRUG MATRIX
Delta-type opioid receptor GPCR Ki 5.63 DRUG MATRIX
Acetylcholinesterase Enzyme IC50 6.40 DRUG MATRIX
Cytochrome P450 2C9 Enzyme IC50 5.70 DRUG MATRIX
G-protein coupled estrogen receptor 1 GPCR EC50 6.50 WOMBAT-PK
Interleukin-6 Cytokine IC50 8.05 WOMBAT-PK
Tyrosine-protein kinase Fyn Kinase IC50 5.44 DRUG MATRIX
Bile acid receptor Nuclear hormone receptor IC50 4.94 CHEMBL
Substance-K receptor GPCR Ki 5.88 DRUG MATRIX
Phospholipase D1 Enzyme IC50 5.40 CHEMBL
Phospholipase D2 Enzyme IC50 5.47 CHEMBL
Complement C5 Secreted Kd 6.15 CHEMBL
Mu-type opioid receptor GPCR Ki 6.32 DRUG MATRIX
HLA class I histocompatibility antigen, A-3 alpha chain Unclassified Kd 4.66 CHEMBL
D(1A) dopamine receptor GPCR Ki 5.71 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 5.83 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 6.07 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.63 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 5.66 CHEMBL
Estrogen receptor Transcription factor Ki 9.43 CHEMBL
Estrogen receptor beta Transcription factor Ki 8.56 CHEMBL
C-8 sterol isomerase Enzyme Ki 7.18 CHEMBL
Cruzipain Enzyme IC50 4.48 CHEMBL
Estrogen receptor Transcription factor IC50 8.73 CHEMBL

External reference:

IDSource
4024098 VUID
N0000022103 NUI
D02217 KEGG_DRUG
82640-04-8 SECONDARY_CAS_RN
4021080 VANDF
4024098 VANDF
C0244404 UMLSCUI
CHEBI:8772 CHEBI
RAL PDB_CHEM_ID
CHEMBL81 ChEMBL_ID
CHEMBL1116 ChEMBL_ID
D020849 MESH_DESCRIPTOR_UI
DB00481 DRUGBANK_ID
2820 IUPHAR_LIGAND_ID
5388 INN_ID
YX9162EO3I UNII
5035 PUBCHEM_CID
166551 RXNORM
11500 MMSL
5410 MMSL
83711 MMSL
d04261 MMSL
007282 NDDF
007283 NDDF
109029006 SNOMEDCT_US
395856004 SNOMEDCT_US
419530003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Evista HUMAN PRESCRIPTION DRUG LABEL 1 0002-4184 TABLET 60 mg ORAL NDA 33 sections
Evista HUMAN PRESCRIPTION DRUG LABEL 1 0002-4184 TABLET 60 mg ORAL NDA 33 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-7290 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-5295 TABLET, FILM COATED 60 mg ORAL ANDA 20 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6902 TABLET, FILM COATED 60 mg ORAL ANDA 30 sections
Raloxifene Hydrochloride Human Prescription Drug Label 1 16714-213 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 31722-256 TABLET 60 mg ORAL ANDA 20 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-726 TABLET, FILM COATED 60 mg ORAL ANDA 31 sections
Raloxifene Hydrochloride Human Prescription Drug Label 1 43353-253 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43598-505 TABLET, FILM COATED 60 mg ORAL ANDA 30 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-3363 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-3866 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-5458 TABLET 60 mg ORAL ANDA 27 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50228-306 TABLET, FILM COATED 60 mg ORAL ANDA 30 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-694 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Evista HUMAN PRESCRIPTION DRUG LABEL 1 54868-4170 TABLET 60 mg ORAL NDA 29 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60687-266 TABLET 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-7708 TABLET 60 mg ORAL ANDA 27 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-8209 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 65162-057 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 65162-057 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride Human Prescription Drug Label 1 65862-709 TABLET, FILM COATED 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride Human Prescription Drug Label 1 66993-661 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68071-2412 TABLET, FILM COATED 60 mg ORAL ANDA 30 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 69097-825 TABLET 60 mg ORAL ANDA 28 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-2994 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-3046 TABLET 60 mg ORAL ANDA 28 sections
Raloxifene hydrochloride Human Prescription Drug Label 1 71209-082 TABLET, COATED 60 mg ORAL ANDA 28 sections
Raloxifene hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71335-1460 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Raloxifene Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71335-1663 TABLET 60 mg ORAL ANDA 27 sections